This study aimed to investigate the therapeutic efficacy of Fufang Longdan Mixture (FLM) in treating MS-P comorbidity, elucidate its mechanism through the miR-29a-5p/IGF-1R axis and evaluate treatment responses between APOE−/− and C57BL/6 mice. This evidence concerns the gene IGF1R and myeloid sarcoma.